Confused About Whole Genome vs SNP Array Testing? Here's What You Actually Need.

Your APOE gene encodes a protein that manages cholesterol transport in your bloodstream and brain. It’s essential for clearing amyloid proteins from your brain and maintaining cognitive function as you age. The normal version keeps your brain clear. A variant version allows accumulation of plaques and tangles associated with cognitive decline.

APOE comes in three main forms: E2, E3, and E4. People with the E4 variant, carried by roughly 15-20% of European ancestry populations, have a significantly elevated risk for cognitive decline and Alzheimer’s disease, especially if they carry two E4 copies. The E4 protein is less efficient at clearing amyloid from the brain. Your risk rises even more if you also have other risk factors like poor sleep, chronic inflammation, or metabolic dysfunction.

You might experience this as brain fog that doesn’t clear with sleep, difficulty retaining new information, or a nagging worry that your memory isn’t as sharp as it used to be. For many people with E4 variants, cognitive symptoms appear earlier than expected, sometimes starting in the 40s or 50s rather than later in life.

Your MTHFR gene codes for an enzyme that converts folate from food into methylfolate, the form your cells actually use for the methylation cycle. The methylation cycle is your cellular on-off switch for thousands of biological processes: energy production, neurotransmitter synthesis, DNA repair, immune function. Without efficient methylation, none of those processes run properly.

The MTHFR C677T variant, carried by roughly 40% of people with European ancestry, reduces enzyme efficiency by 40-70%. That means your cells are converting B vitamins into usable energy at a fraction of the rate they should be, even if you eat a perfect diet and take regular B vitamins. The A1298C variant has a milder effect, but compounds the problem if you carry both.

You experience this as persistent fatigue that doesn’t improve with rest, brain fog that lifts slightly with caffeine but never fully clears, mood instability, or difficulty recovering from exercise. Many people with MTHFR variants report that standard B vitamin supplementation makes them feel worse, not better, because they’re taking forms their broken enzyme cannot process.

Your BRCA1 gene encodes a protein that repairs damaged DNA and suppresses tumor formation. It’s one of your cell’s primary defense mechanisms against cancer. When your BRCA1 works normally, it catches mistakes in DNA replication and either fixes them or triggers apoptosis (cell death) before cancer can develop. A healthy BRCA1 is one of your most powerful cancer prevention tools.

BRCA1 mutations (not variants, but actual mutations that disable the gene) are rare, carried by roughly 1 in 300 to 1 in 500 people depending on ancestry. Women who carry a BRCA1 mutation have a 45-87% lifetime risk for breast cancer and 10-40% risk for ovarian cancer. Men have elevated risks for prostate and pancreatic cancer. These aren’t small increased risks; they’re fundamental changes to your cancer trajectory.

Most people don’t experience BRCA1 mutations as a symptom until cancer appears. That’s why testing is so valuable: you can catch the mutation before disease develops and make informed decisions about screening, prevention, and family planning. If you have a family history of early-onset breast cancer, ovarian cancer, or cancer in multiple family members, BRCA1 status is critical information.

Your BRCA2 gene works similarly to BRCA1: it repairs DNA damage and suppresses tumor formation. Both are critical. BRCA2 mutations have slightly different cancer patterns than BRCA1 mutations, though the mechanism is the same. When your BRCA2 is broken, DNA damage accumulates faster, and cancer risk rises dramatically.

BRCA2 mutations are also rare, carried by roughly 1 in 300 to 1 in 500 people. Women with BRCA2 mutations have a 45-84% lifetime breast cancer risk and 10-20% ovarian cancer risk. Men with BRCA2 mutations have substantially elevated risk for breast cancer (6-27%), prostate cancer, and pancreatic cancer. The male breast cancer risk from BRCA2 is actually higher than from BRCA1.

Like BRCA1, most people don’t know they carry a BRCA2 mutation until cancer appears or until they test. If you have a family history of cancer, Jewish ancestry, or relatives diagnosed with cancer before age 50, BRCA2 testing is essential baseline information for your health decisions.

Your CYP2D6 gene codes for an enzyme that metabolizes roughly 25% of all medications, including many psychiatric drugs, pain medications, and blood pressure medications. How efficiently your CYP2D6 works determines whether a medication reaches an effective dose in your bloodstream or accumulates to toxic levels. This gene is one of the most important determinants of whether a medication will help you or harm you.

CYP2D6 comes in multiple functional copies, and people can be slow metabolizers, normal metabolizers, or ultra-rapid metabolizers. Roughly 7-10% of European ancestry populations are slow metabolizers; roughly 1-5% are ultra-rapid metabolizers. If you’re a slow metabolizer taking a standard dose of an antidepressant or pain medication, the drug accumulates in your bloodstream to levels that cause side effects: nausea, sedation, cognitive blunting, or sexual dysfunction. If you’re an ultra-rapid metabolizer, the standard dose is ineffective because you clear it too fast.

You might experience this as taking a medication that “doesn’t work” or causes intolerable side effects while your doctor insists the dose is correct. You might have been labeled as medication-resistant or psychiatric-medication-sensitive when the real problem is that your genetics make standard dosing inappropriate for your metabolism.

Your VDR gene codes for the receptor protein that allows your cells to actually use vitamin D. You can have perfect vitamin D blood levels, but if your VDR receptor doesn’t work efficiently, your cells can’t access that vitamin D. It’s like having money in your bank account but a broken ATM. VDR efficiency is one of the most underappreciated determinants of vitamin D status.

VDR variants (BsmI, FokI, TaqI) are common, carried by roughly 30-50% of the population depending on ancestry. People with certain VDR variants have significantly reduced cellular uptake of vitamin D, requiring higher blood levels to achieve the same biological effect. This impairs immune function, bone health, and mitochondrial energy production. You can be taking 4,000 IU daily of vitamin D and still have a functionally deficient level because your cells can’t absorb it.

You might experience this as weak immune function (catching every cold), poor bone health despite adequate calcium, or persistent fatigue and muscle weakness. Many people with VDR variants report that they feel significantly better only when their vitamin D levels are higher than conventional recommendations suggest.